GLP-1s, Muscle Preservation, and the Future of Weight Loss in Longevity Medicine

Concerns about muscle loss during GLP-1 treatment arise from a legitimate clinical issue. People losing substantial weight often lose some lean tissue, and medication-related appetite suppression can make adequate nutrition harder to maintain. If food intake falls while resistance exercise remains absent, an older adult or someone with low baseline strength may become more vulnerable to functional decline.

Calorie restriction and bariatric surgery can also reduce lean tissue. The important questions concern the amount and composition of weight lost, the person’s starting reserve and whether strength and physical capability are being maintained. The wider metabolic benefits and clinical considerations of these medications are discussed in GLP-1 Medications and Metabolic Health.

For the broader framework, read Healthy Bones and Muscles in Longevity Medicine, which connects nutrition, training, skeletal health and clinical assessment.

Lean Mass and Skeletal Muscle Are Different Measurements

DEXA separates body composition into fat, lean soft tissue and bone mineral content. Skeletal muscle contributes to the lean compartment, but that compartment also includes body water, organs, connective tissue and other nonfat tissues. Changes in hydration and glycogen-associated water can affect the measurement during weight reduction.

A decline in DEXA lean mass therefore cannot be converted directly into an equivalent amount of contractile muscle loss. It still deserves review, particularly when accompanied by worsening strength or poor intake. Body-composition findings become more clinically informative when considered alongside chair-rise performance, walking capacity, training progress and other functional measures.

What Semaglutide and Tirzepatide Studies Show

In an exploratory DEXA analysis of STEP 1, semaglutide-treated participants lost approximately 15% of body weight over 68 weeks. Total fat mass declined by 19.3%, regional visceral fat by 27.4% and total lean body mass by 9.7%. Fat declined more than lean tissue, so the proportion of body weight represented by lean mass increased.

The SURMOUNT-1 DEXA substudy reported a similar overall pattern with tirzepatide. At 72 weeks, body weight declined by 21.3%, fat mass by 33.9% and lean mass by 10.9%. Approximately 75% of the weight lost was fat and 25% was lean mass, with similar proportions in the placebo group despite much smaller total weight loss.

These are group averages from study subpopulations. They confirm meaningful lean-tissue changes while showing substantial improvements in adiposity. They do not determine how much muscle an individual patient will lose or how that change will affect function.

Comparing Medication and Lifestyle Weight Loss

A 2026 systematic review compared lean-mass changes across randomized trials of incretin therapies and intensive lifestyle interventions. The reported proportions of weight lost as lean tissue were broadly overlapping, with variation by medication and intervention. Lifestyle programs that incorporated resistance training showed more favorable lean-mass preservation.

Comparisons across separate trials are influenced by participant characteristics, weight-loss magnitude, measurement methods and intervention design. They do not establish that every medication and lifestyle approach has equivalent effects. The findings nevertheless support a practical conclusion: what accompanies weight loss is important to the outcome.

Another 2026 systematic review emphasized the need to pair obesity pharmacotherapy with nutritional and exercise interventions. Functional outcomes remain less consistently measured than body composition, leaving important questions about strength and longer-term muscle health.

Resistance Training During Treatment

Resistance exercise challenges the muscles to generate force and supports the adaptations needed to maintain strength. Machines, free weights, bands and body-weight exercises can all be used, with the program adjusted to experience, orthopedic concerns and recovery capacity.

For many adults, two or three weekly sessions provide a workable structure. The program should address the major muscle groups and progress as capacity improves. People with frailty, significant weakness or osteoporosis may benefit from supervised instruction and appropriate modifications.

Aerobic activity remains important for endurance, cardiovascular fitness and metabolic health. Resistance exercise adds a different stimulus, while balance and weight-bearing activities can contribute to fall prevention and skeletal care. The plan should support the abilities the patient wants to retain, including stairs, lifting, walking and travel.

Read more in Muscle Mass and Metabolic Health.

Nutrition When Appetite Is Reduced

Early satiety and smaller portions can reduce protein, fiber and micronutrient intake along with calories. A dietary review should therefore assess what the person is actually eating, rather than assume that weight loss reflects adequate nutrition.

A protein range of approximately 1.2–1.6 grams per kilogram of target or adjusted body weight daily can be useful for many adults during fat loss. The recommendation requires individualization for kidney function, age, body composition, activity and medical history. Adequate total energy remains important, particularly when intake is persistently low.

Protein-containing foods can be distributed across meals according to tolerance. Fish, eggs, yogurt, cottage cheese, poultry, tofu and legumes offer different ways to meet the target. A protein supplement may help when food intake is inadequate, while hydration, fiber and gastrointestinal symptoms require attention as well.

Our Nutrition on GLP-1 Medication article and Protein After 50 guide explore these decisions.

DEXA, SECA and Physical Function

A whole-body DEXA composition scan estimates fat mass, lean tissue and visceral fat. Diagnostic bone density requires the appropriate skeletal scans, usually at the hip and spine. These measurements provide complementary information and should not be treated as interchangeable.

SECA body-composition analysis can provide trend information between DEXA assessments. Hydration, meals, activity and testing conditions affect bioimpedance estimates, so consistency and clinical interpretation matter.

Strength and function belong alongside these measurements. A patient may have a modest lean-tissue decline while improving walking tolerance and strength, whereas another may develop weakness despite a favorable-looking body-fat percentage. Changes in daily capability help determine whether a treatment adjustment is needed.

Patients Who Need Closer Monitoring

Older adults with low muscle reserve, frailty, limited mobility or recent illness may have less capacity to tolerate additional lean-tissue loss. Repeated restrictive dieting, low protein intake and inactivity can add concern. Low bone density deserves attention because reduced loading, falls and nutritional inadequacy can complicate skeletal health.

Unexplained weakness may also warrant evaluation for medications, thyroid disease, sleep disorders or other illness. Hormone assessment can be relevant when supported by symptoms and history, but muscle loss alone does not establish an indication for testosterone or menopausal hormone treatment.

These findings influence the pace of weight loss, nutritional support, training plan and follow-up rather than automatically excluding medication treatment.

When Appetite Suppression Becomes Excessive

Persistent inability to meet nutritional needs, vomiting, dehydration, worsening fatigue or declining exercise tolerance warrants review with the prescribing clinician. Titration may need to be delayed, or treatment adjusted according to the medication’s labeling and the individual’s response.

Dosing decisions should follow the specific product, indication, benefits and tolerability. An appropriate maintenance dose is a clinical decision; achieving greater appetite suppression is not sufficient evidence that treatment is working well.

Related discussions include GLP-1 Microdosing and GLP-1 Maintenance Dosing and Weight Regain.

Where Creatine Fits

Creatine monohydrate has evidence for supporting strength and lean-tissue gains alongside resistance training in older adults. Its rationale during GLP-1 treatment is to support the training plan, rather than to act as a proven treatment for medication-associated lean-mass loss.

RetzlerRx® Creatine Monohydrate may be considered when appropriate. Medical history and kidney concerns should be reviewed, and supplementation should remain coordinated with food intake and exercise.

Read more in Creatine in Longevity Medicine.

The HormoneSynergy® Care Pathway

HormoneSynergy® provides GLP-1 and weight-management treatment within concierge longevity care following the Optimal Aging Assessment. Weight loss is no longer offered as a separate stand-alone program.

The comprehensive assessment allows Dr. Kathryn Retzler to consider metabolic health, cardiovascular risk, body composition, skeletal health and other relevant findings before recommending treatment. Ongoing care provides the setting for nutrition planning, exercise guidance, medication review and monitoring.

In HormoneSynergy®’s clinical experience, dramatic muscle deterioration has not been typical among patients actively following a plan that includes adequate protein, resistance exercise and appropriate medication management. This is a clinical observation rather than a controlled comparison, and individual responses still require assessment.

The Weight Loss for Longevity resource describes the broader approach. Treatment progress is considered through metabolic improvement, nutritional adequacy and maintained physical capability alongside the amount of weight lost.

Frequently Asked Questions

Do GLP-1 medications cause muscle loss?

Substantial weight loss can include lean tissue, including some muscle. Current evidence does not establish a unique medication-induced muscle-wasting disorder, but strength, nutrition and body composition should be monitored.

How much lean mass was lost with tirzepatide?

In the SURMOUNT-1 DEXA substudy, approximately 25% of lost weight was lean mass and 75% was fat. Lean mass includes more than skeletal muscle, and these group averages do not predict an individual response.

How much lean mass was lost with semaglutide?

The exploratory STEP-1 analysis reported a 9.7% reduction in total lean body mass alongside larger reductions in fat and visceral fat. This was a change from baseline lean mass, not the percentage of lost weight that was muscle.

Is lean mass the same as muscle?

No. DEXA lean soft tissue includes muscle, water, organs and other tissues. Interpretation requires context from function, nutrition and testing conditions.

Is medication-related lean-mass loss worse than dieting?

A 2026 comparative meta-analysis found broadly overlapping proportions with incretin therapy and intensive lifestyle interventions. Differences among trials limit direct comparisons, and resistance training was associated with more favorable preservation.

How can muscle be supported during treatment?

Adequate nutrition, individualized protein intake, progressive resistance training, recovery and clinical review of weight-loss pace and medication tolerability provide the foundation.

Is walking enough?

Walking supports endurance and cardiovascular health. Progressive resistance training adds a more specific stimulus for maintaining strength during weight loss.

What if I cannot eat enough?

Persistent difficulty eating or drinking adequately should be discussed with the prescriber. Titration or treatment may need adjustment.

Does creatine prevent GLP-1 muscle loss?

That has not been established. Creatine can support resistance-training outcomes and may fit a broader muscle-preservation plan.

Why use DEXA during weight management?

DEXA composition testing estimates fat, lean tissue and visceral fat changes. Appropriate skeletal scans assess bone density, while strength testing provides separate functional information.

Is HormoneSynergy® GLP-1 care a stand-alone program?

No. GLP-1 and weight-management treatment is provided within concierge care following the Optimal Aging Assessment.

Related HormoneSynergy® Reading

• Healthy Bones and Muscles in Longevity Medicine
• Body Composition and Longevity Medicine
• Metabolic Health and Longevity Medicine
• GLP-1s, Muscle Preservation and the Future of Weight Loss
• DEXA Testing
• Longevity Medicine Resource Library

For a broader discussion of how GLP-1 therapies affect weight regulation, glucose control and cardiometabolic health, see GLP-1 Medications and Metabolic Health.

Selected Research and Clinical Guidance

• Eisa N, et al. Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. 2026.
• Laverde LP, et al. Effect of GLP-1 receptor agonists at doses for obesity management on muscle health: systematic review and meta-analysis of randomized controlled trials. 2026.
• Look M, et al. Body composition changes during weight reduction with tirzepatide in SURMOUNT-1. 2025.
• Wilding JPH, et al. Impact of Semaglutide on Body Composition: Exploratory Analysis of STEP 1. 2021.
• Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint clinical advisory. 2025.

Editorial Transparency

HormoneSynergy® provides physician-guided GLP-1 treatment within its concierge longevity medicine program and offers body-composition testing and nutritional guidance discussed in this article. RetzlerRx® is the clinic’s supplement label. These services and products are disclosed so readers can evaluate the clinical discussion with an understanding of the practice’s commercial relationships. Treatment decisions are individualized; no supplement is established as a treatment for GLP-1-associated lean-tissue loss.

Medical Disclaimer

This article is for general education and is not a diagnosis or a substitute for individualized medical advice. GLP-1 medication decisions, nutrition targets, exercise plans and interpretation of body-composition measurements should be discussed with a qualified healthcare professional familiar with your medical history. Do not change prescribed medication without consulting your prescriber.

AI Transparency

HormoneSynergy® may use AI-assisted tools to support research organization, drafting and editorial review. Medical claims and recommendations are intended to reflect the cited literature and HormoneSynergy®’s clinical editorial standards. AI does not provide individualized medical judgment or replace clinician review.